https://mb.cision.com/Public/18595/3760702/986c42489e4f9676_800x800ar.png
** UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to =
Discover New Modalities for the Treatment of Immune-related Diseases and Ca=
ncer
------------------------------------------------------------
=C2=B7 UCB=E2=80=99s expertise in macrocyclic peptide discovery, using its =
proprietary mRNA-display platform, ExtremeDiversity=E2=84=A2, will aid Aric=
eum=E2=80=99s discovery of treatments for solid tumors
=C2=B7 Ariceum=E2=80=99s expertise in radiopharmaceuticals and labelling te=
chnology will aid UCB=E2=80=99s discovery of treatments for immune-related =
diseases
Brussels (Belgium) and Berlin (Germany), 11th May 2023 - 07:30 CET - UCB (E=
URONEXT BRUSSELS: UCB), a global biopharmaceutical company and Ariceum Ther=
apeutics (Ariceum), a private biotech company developing radiopharmaceutica=
l products for the diagnosis and treatment of certain hard-to-treat cancers=
, today announced an exclusive strategic research collaboration agreement t=
o identify and develop novel systemic targeted radiopharmaceuticals for the=
treatment of immune-related diseases and solid tumors .=C2=A0
Under the terms of the research collaboration, UCB and Ariceum will utilize=
each other=E2=80=99s proprietary technology platforms to enable the discov=
ery of peptide-radioisotope conjugates as potential therapeutics for immune=
-related diseases and cancer. Ariceum will also gain access to UCB=E2=80=99=
s expertise to discover novel synthetic macrocyclic peptides using its mRNA=
-display technology platform, ExtremeDiversity=E2=84=A2. UCB will benefit f=
rom Ariceum=E2=80=99s expertise in the field of radiochemistry and labellin=
g technology to enhance its ability to explore how this technology might le=
ad to the discovery of highly differentiated products for immune-related di=
seases. Both companies will have the opportunity to explore several targets=
under this research collaboration.
Dhaval Patel, Chief Scientific Officer of UCB, commented: "The collaboratio=
n with Ariceum further enhances our strategic drug discovery capabilities a=
nd provides UCB with the opportunity to learn and explore the potential of =
this modality in our drive to continuously innovate. We look forward to wor=
king with Ariceum=E2=80=99s scientists and are eager to leverage the techno=
logy platforms and disease expertise at each company.=E2=80=9D
Manfred R=C3=BCdiger, PhD, Chief Executive Officer of Ariceum Therapeutics,=
said: =E2=80=9CWe are excited about this strategic collaboration between U=
CB and Ariceum which aims to broaden Ariceum=E2=80=99s pipeline with potent=
ially several new programs at discovery stage. =C2=A0Through this partnersh=
ip, Ariceum will have access to a unique library that will be used to scree=
n against targets of interest for oncology for which current targeted appro=
aches have failed while working with UCB on enabling targeted systemic radi=
otherapy approaches in other areas of severe diseases.=E2=80=9D=C2=A0
For further information=C2=A0
UCB
R&D Communications - Scott Fleming;=C2=A0
Scott.fleming@ucb.com / T +44 7702777378
Corporate Communications, Media Relations - Laurent Schots
laurent.schots@ucb.com / T +3225599264=C2=A0
Investor Relations - Antje Witte
antje.witte@ucb.com / T +3225599414
Ariceum Therapeutics
Manfred R=C3=BCdiger, CEO
info@ariceum-therapeutics.com
Optimum Strategic Communications - Hollie Vile, Charlotte Hepburne-Scott, Z=
oe Bolt, Elena Bates
ariceum@optimumcomms.com / T +44 20 3882 9621
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or the central nervous system. With approximately 8 700 people i=
n approximately 40 countries, the company generated revenue of =E2=82=AC 5.=
5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB).
About Ariceum Therapeutics=C2=A0
Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceut=
ical company focused on the diagnosis and precision treatment of certain ne=
uroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum =
is an anagram of =E2=80=98Marie Curie=E2=80=99 whose discovery of radium an=
d polonium have been huge contributions to finding treatments for cancer.=
=C2=A0
Ariceum Therapeutics, launched in 2021, acquired all rights from Ipsen. Ips=
en remains a shareholder in the Company. Ariceum is headquartered in Berlin=
, with operations in Germany, Switzerland and Australia and activities curr=
ently across Europe, North America.
Ariceum is led by a highly experienced management team and supported by spe=
cialist investors including EQT Life Sciences (formerly LSP), HealthCap, =
=C2=A0Pureos Bioventures, Andera Partners and Earlybird Venture Capital. Fo=
r further information, please visit www.ariceum-therapeutics.com
Forward looking statements - UCB
This press release may contain forward-looking statements including, withou=
t limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =
=E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=
=E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim=
ates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccont=
inue=E2=80=9D and similar expressions. These forward-looking statements are=
based on current plans, estimates and beliefs of management. All statement=
s, other than statements of historical facts, are statements that could be =
deemed forward-looking statements, including estimates of revenues, operati=
ng margins, capital expenditures, cash, other financial information, expect=
ed legal, arbitration, political, regulatory or clinical results or practic=
es and other such estimates and results. By their nature, such forward-look=
ing statements are not guarantees of future performance and are subject to =
known and unknown risks, uncertainties and assumptions which might cause th=
e actual results, financial condition, performance or achievements of UCB, =
or industry results, to differ materially from those that may be expressed =
or implied by such forward-looking statements contained in this press relea=
se. Important factors that could result in such differences include: the gl=
obal spread and impact of COVID-19, changes in general economic, business a=
nd competitive conditions, the inability to obtain necessary regulatory app=
rovals or to obtain them on acceptable terms or within expected timing, cos=
ts associated with research and development, changes in the prospects for p=
roducts in the pipeline or under development by UCB, effects of future judi=
cial decisions or governmental investigations, safety, quality, data integr=
ity or manufacturing issues; potential or actual data security and data pri=
vacy breaches, or disruptions of our information technology systems, produc=
t liability claims, challenges to patent protection for products or product=
candidates, competition from other products including biosimilars, changes=
in laws or regulations, exchange rate fluctuations, changes or uncertainti=
es in tax laws or the administration of such laws, and hiring and retention=
of its employees. There is no guarantee that new product candidates will b=
e discovered or identified in the pipeline, will progress to product approv=
al or that new indications for existing products will be developed and appr=
oved. Movement from concept to commercial product is uncertain; preclinical=
results do not guarantee safety and efficacy of product candidates in huma=
ns. So far, the complexity of the human body cannot be reproduced in comput=
er models, cell culture systems or animal models. The length of the timing =
to complete clinical trials and to get regulatory approval for product mark=
eting has varied in the past and UCB expects similar unpredictability going=
forward. Products or potential products, which are the subject of partners=
hips, joint ventures or licensing collaborations may be subject to differen=
ces disputes between the partners or may prove to be not as safe, effective=
or commercially successful as UCB may have believed at the start of such p=
artnership. UCB=E2=80=99s efforts to acquire other products or companies an=
d to integrate the operations of such acquired companies may not be as succ=
essful as UCB may have believed at the moment of acquisition. Also, UCB or =
others could discover safety, side effects or manufacturing problems with i=
ts products and/or devices after they are marketed. The discovery of signif=
icant problems with a product similar to one of UCB=E2=80=99s products that=
implicate an entire class of products may have a material adverse effect o=
n sales of the entire class of affected products. Moreover, sales may be im=
pacted by international and domestic trends toward managed care and health =
care cost containment, including pricing pressure, political and public scr=
utiny, customer and prescriber patterns or practices, and the reimbursement=
policies imposed by third-party payers as well as legislation affecting bi=
opharmaceutical pricing and reimbursement activities and outcomes. Finally,=
a breakdown, cyberattack or information security breach could compromise t=
he confidentiality, integrity and availability of UCB=E2=80=99s data and sy=
stems.=C2=A0
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products described in this press release will be submitt=
ed or approved for sale or for any additional indications or labelling in a=
ny market, or at any particular time, nor can there be any guarantee that s=
uch products will be or will continue to be commercially successful in the =
future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release and it does not reflect any potenti=
al impact from the evolving COVID-19 pandemic, unless indicated otherwise. =
UCB is following the worldwide developments diligently to assess the financ=
ial significance of this pandemic to UCB. UCB expressly disclaims any duty =
to update any information contained in this press release, either to confir=
m the actual results or to report or reflect any change in its forward-look=
ing statements with regard thereto or any change in events, conditions or c=
ircumstances on which any such statement is based, unless such statement is=
required pursuant to applicable laws and regulations.=C2=A0
Additionally, information contained in this document shall not constitute a=
n offer to sell or the solicitation of an offer to buy any securities, nor =
shall there be any offer, solicitation or sale of securities in any jurisdi=
ction in which such offer, solicitation or sale would be unlawful prior to =
the registration or qualification under the securities laws of such jurisdi=
ction.
=C2=A0
GenericFile
UCB PR Ariceum Collaboration ENG (https://mb.cision.com/Public/18595/376070=
2/ab842311a5b58f19.pdf)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x135905x1x6868579x2400=
0x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
26/04/2024 20:00
25/04/2024 18:00
25/04/2024 07:01
23/04/2024 20:00
22/04/2024 07:01
19/04/2024 20:00
17/04/2024 07:01
12/04/2024 20:00
12/04/2024 18:01
12/04/2024 07:01